All questionsSpecific populations: Rinvoq (upadacitinib) in rheumatoid arthritis3 questions · 1 sourceSpecific populationsDoes RINVOQ need a dose adjustment for kidney or liver impairment?“In RA, PsA, AS, nr-axSpA, and GCA: No dose adjustment is required for mild, moderate, or severe renal impairment.1 No dose adjustment is required for mild or moderate hepatic impairment.1 RINVOQ is not recommended in patients with1: Active hepatitis B or hepatitis C Severe hepatic impairment (Child-Pugh C) RINVOQ has not been studied in end-stage renal disease (eGFR <15 mL/min/1.73 m2).1” (opens the source at this quote in a new tab)CopyFlagCan patients breastfeed while taking RINVOQ?“There are no data on the presence of RINVOQ in human milk, the effects on the breastfed infant, or the effects on milk production. Available data in animals have shown the excretion of RINVOQ in milk. Advise patients that breastfeeding is not recommended during treatment with RINVOQ and for 6 days after the last dose.” (opens the source at this quote in a new tab)CopyFlagCan RINVOQ be used during pregnancy?“Based on findings in animal studies, RINVOQ may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with RINVOQ and for 4 weeks after the final dose. Verify pregnancy status of females of reproductive potential prior to starting treatment with RINVOQ.” (opens the source at this quote in a new tab)CopyFlag